Leerink Partners analyst Thomas Smith has maintained their bullish stance on VRDN stock, giving a Buy rating on January 14. Thomas Smith’s rating is based on the promising developments and ...

Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks. Announced Friday as ...

UK pharma major AstraZeneca’s (LSE: AZN) Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Lykos Therapeutics is currently working out ways to fund an additional Phase III study for its MDMA-assisted PTSD therapy following an FDA setback last year. Lykos Therapeutics can’t seem to catch a ...

On Tuesday morning, Biogen hosted an event for Wall Street analysts to better understand the company. One of the key topics discussed, according to Brian Abrahams of RBC Capital Markets, was business ...

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price target at $46.00. Discover outperforming stocks and ...

German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi Sankyo (TYO: 4568). This collaboration marks the start of a cutting-edge ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO ...